The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis
Open accessAbstract
Evidence supporting aspirin and resistant starch (RS) for colorectal cancer prevention comes from epidemiologic and laboratory studies (aspirin and RS) and randomized controlled clinical trials (aspirin). Familial adenomatous polyposis (FAP) strikes young people and, untreated, confers virtually a 100% risk of colorectal cancer and early death. We conducted an international, multicenter, randomized, placebo-controlled trial of aspirin (600 mg/d) and/or RS (30 g/d) for from 1 to 12 years to prevent disease progression in FAP patients from 10 to 21 years of age. In a 2 × 2 factorial design, patients were randomly assigned to the following four study arms: aspirin plus RS placebo; RS plus aspirin placebo; aspirin plus RS; RS placebo plus aspirin placebo; they were followed with standard annual clinical examinations including endoscopy. The primary endpoint was polyp number in the rectum and sigmoid colon (at the end of intervention), and the major secondary endpoint was size of the largest polyp. A total of 206 randomized FAP patients commenced intervention, of whom 133 had at least one follow-up endoscopy and were therefore included in the primary analysis. Neither intervention significantly reduced polyp count in the rectum and sigmoid colon: aspirin relative risk = 0.77 (95% CI, 0.54–1.10; versus nonaspirin arms); RS relative risk = 1.05 (95% CI, 0.73–1.49; versus non-RS arms). There was a trend toward a smaller size of largest polyp in patients treated with aspirin versus nonaspirin—mean 3.8 mm versus 5.5 mm for patients treated 1 or more years (adjusted P = 0.09) and mean 3.0 mm versus 6.0 mm for patients treated more than 1 year (P = 0.02); there were similar weaker trends with RS versus non-RS. Exploratory translational endpoints included crypt length (which was significantly shorter in normal-appearing mucosa in the RS group over time) and laboratory measures of proliferation (including Ki67). This clinical trial is the largest ever conducted in the setting of FAP and found a trend of reduced polyp load (number and size) with 600 mg of aspirin daily. RS had no clinical effect on adenomas. Cancer Prev Res; 4(5); 655–65. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Nutritional Implications Of Resistant Starch
Asp, N.-G., van Amelsvoort, J. M. M., & Hautvast, J. G. A. J. (1996) · Nutrition Research Reviews · doi:10.1079/nrr19960004 · Cited by 206
Cited by
Burn, J., Gerdes, A.-M., Macrae, F., Mecklin, J.-P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61049-0 · Cited by 952
Self-citationInflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
Monahan, K. J., Bradshaw, N., Dolwani, S., Desouza, B., Dunlop, M. G., East, J. E., Ilyas, M., Kaur, A., Lalloo, F., Latchford, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319915 · Cited by 484
Self-citationBurn, J., Sheth, H., Elliott, F., Reed, L., Macrae, F., Mecklin, J.-P., Möslein, G., McRonald, F. E., Bertario, L., Evans, D. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30366-4 · Cited by 431
Self-citationMolecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
Colussi, D., Brandi, G., Bazzoli, F., & Ricciardiello, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816365 · Cited by 429
Metadata
- Authors
- Burn, J., Bishop, D. T., Chapman, P. D., Elliott, F., Bertario, L., Dunlop, M. G., Eccles, D., Ellis, A., Evans, D. G., Fodde, R., Maher, E. R., Möslein, G., Vasen, H. F. A., Coaker, J., Phillips, R. K. S., Bülow, S., & Mathers, J. C.
- Venue
- Cancer Prevention Research
- Published
- 2011-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 655-665
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- OpenAlex
- W2158718772
- Cited by
- 241
- References
- 2
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. https://app.cochat.ai/papers/10.1158/1940-6207.capr-11-0106
- The paper
- Burn, J., Bishop, D. T., Chapman, P. D., Elliott, F., Bertario, L., Dunlop, M. G., Eccles, D., Ellis, A., Evans, D. G., Fodde, R., Maher, E. R., Möslein, G., Vasen, H. F. A., Coaker, J., Phillips, R. K. S., Bülow, S., & Mathers, J. C. (2011). A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-11-0106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.